LMAT

LeMaitre Vascular, Inc. is a provider of devices, implants, and services for the treatment of peripheral vascular disease. The Company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and other specialties, such as cardiac surgeons, general surgeons, and neurosurgeons. Its portfolio of product lines is used to treat vascular disease, which used in open vascular surgery and dialysis access. It also offers human vascular and cardiac tissue cryopreservation services. Its principal product lines include anastomotic clips, biologic vascular and dialysis grafts, biologic vascular and cardiac patches, carotid shunts, embolectomy and occlusion catheters, radiopaque marking tape, synthetic vascular and dialysis grafts, and valvulotomes. Its principal biologic offerings include vascular and cardiac patches as well as vascular and dialysis grafts. Its product offerings are sold primarily in the United States, Europe, Canada, and Asia Pacific.

Wall Street analysts forecast LMAT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LMAT is 98.75 USD with a low forecast of 95.00 USD and a high forecast of 108.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

LeMaitre Vascular Inc revenue for the last quarter amounts to 61.05M USD, increased 11.36 % YoY.

LeMaitre Vascular Inc. EPS for the last quarter amounts to 0.71 USD, increased 44.90 % YoY.

LeMaitre Vascular Inc (LMAT) has 651 emplpoyees as of January 10 2026.

Today LMAT has the market capitalization of 1.93B USD.